2 hrs ago
Recent Study: Angina (Angina Pectoris) Global Clinical Trials Review, H2, 2013
This report provides elemental information and data relating to the clinical trials on Angina .
Sat Dec 07, 2013
New Report Available: Gilead Sciences, Inc. - SWOT, Strategy and Corporate Finance Report
The report covers the company's structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360deg view of the company.
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...
The data show that among patients with chronic lymphocytic leukemia who received at least eight weeks of GS-9973 monotherapy, 97 percent experienced a reduction in lymph node size.
FDA approves faster, easier treatment for hepatitis C
All you have to do is look at quarterback Cristian Solano's numbers to see why he could be a good... Sovaldi, a new medication for hepatitis C that can be paired with other drugs to make treatment of the liver-damaging disease faster, easier and more effective, got approval from the Food and Drug Administration Friday.
Gilead Sciences Sees Unusually High Options Volume
Gilead Sciences was the target of unusually large options trading activity on Friday.
Fri Dec 06, 2013
Inside Bay Area
Biz Break: Job growth spikes, Wall Street likes; Google, Gilead gain
Today: The unemployment rate in the United States hits a five-year low, and investors celebrate by pushing stocks higher, including Google and Gilead.
Employers added 203,000 jobs in November, and the unemployment rate fell to 7 percent, a five-year low.
The Campbell Reporter
Gilead's breakthrough hepatitis C drug approved by FDA
Federal health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
FDA approves breakthrough hepatitis C drug
Gilead Sciences Inc. said on Friday that the federal government has approved its much anticipated hepatitis C drug, that is expected to offer a faster cure to millions of people infected with the liver-destroying virus.
Thu Dec 05, 2013
The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Wed Dec 04, 2013
Gilead CEO John Martin pockets $19 million in stock sale
Gilead Sciences Inc. Chairman and CEO John Martin netted nearly $19 million by selling 282,242 shares Monday at nearly 10 times the price at which he exercised options to buy the shares.
New target identified for preventing bone destruction in diseases such as arthritis and cancer
The skeleton is constantly being remodelled by the breakdown of old bone by cells called osteoclasts and the formation of new bone by cells called osteoblasts.
Tue Dec 03, 2013
The Motley Fool
Can Veeva Systems' Partnership With Salesforce.com Lift Its Earnings?
With big players like Merck , Gilead Sciences , and several other major pharma and biotech players on its customer list, Veeva shares soared on its opening day.
Mon Dec 02, 2013
Gilead Sciences to Present at the Nasdaq Omx 30th Investor Program on Tuesday, December 3
Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the NASDAQ OMX 30th Investor Program in London.
Weekly Top Insider Sells: GOOG, FCX, GILD, P, OCN
According to GuruFocus Insider Data , the largest insider sells during the past week were: Google Inc, Freeport-McMoRan Copper & Gold, Gilead Sciences Inc, Pandora Media Inc, and Ocwen Financial Corporation.
Gilead Sciences, Inc. Uses the PHT Corporation LogPad System for 1st...
World's most widely used ePRO System leveraged on 14-country, 104-site, 927-patient trial; primary and secondary endpoints achieved, with 98% patient compliance )--The PHT Corporation LogPadA System was used by Gilead Sciences, Inc. on the Phase 4 TERISA trial which measured the antianginal effect of Ranolazine in T2DM patients in the therapeutic ... (more)
Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences
Idenix Pharmaceuticals today announced that it has filed two lawsuits against Gilead Sciences, Inc. : a patent infringement lawsuit in the United States District Court in Boston, Massachusetts and a separate patent infringement and interference lawsuit in the United States District Court in Wilmington, Delaware.
Thu Nov 28, 2013
Wed Nov 27, 2013
The Motley Fool
Last Week's 5 Top-Performing Stocks on the S&P 500
While most Foolish investors are focused on long-term investing, it's also wise to stay apprised of short-term movements in stock prices, as the reasons for these moves could be relevant to investors' long-term investment theses.
Product Reviews, Recognitions, FDA Responses, and New Leadership...
Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare NEW YORK, November 27, 2013 /PRNewswire via COMTEX/ -- Editor Note: For more information about this release, please scroll to bottom.